Interestingly, they did not find a protection against recurrent hospitalization among VITAL participants whose suffered form heart failure but who were not Type 2 diabetics. The researchers also saw a benefit of omega-3s on preventing recurrent heart failure hospitalizations among the T2D group. That compared to 5.2% of the placebo group. Within the window of the first follow up visit in VITAL, which averages about 5.3 years, 3.6% of the T2D group receiving the vitamin D-omega-3s intervention had been hospitalized for heart failure. About 1,700 of VITAL participants had been diagnosed with T2D.Īfter crunching the preexisting data, the researchers concluded that the omega-3s intervention had a positive effect on preventing hospitalization for heart failure among VITAL participants who had been diagnosed with T2D. The authors of the present study excluded 36 of those who had chronic heart failure at the time of enrollment in VITAL. The study ran from 2011 to 2017 and included more than 25,000 participants. The VITAL study provided participants with 2,000 IU of vitamin D and 460 mg of eicosapentaenoic acid and 380 mg of docosahexaenoic acid ) a day, compared to placebo. Mortality is high, and the costs of this care are high as well. The researchers noted that prior studies have shown that 83% of patients diagnosed with heart failure will be hospitalized at least once, and 67% will be hospitalized two or more times. These can leave the heart too weak or too stiff to properly perform its function. The condition can be caused by coronary artery disease or high blood pressure. ![]() In these cases blood can back up and fluid can accumulate in the lungs, leading to shortness of breath. Heart failure-sometimes referred to as congestive heart failure-is a condition in which the heart muscle doesn't pump blood as well as it should. The researchers were looking to see what role T2D and race might have on the effects of omega-3 supplements on the incidence of HF hospitalization. The research is another ancillary study of the VITAL (Vitamin D and Omega-3 Trial). It was the work of researchers associated with Harvard Medical School, Cedars Sinai Medical Center in Los Angeles and other hospitals and institutions. The new paper was published in the journal JACC Heart Failure.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |